| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 44 | 2024 | 260 | 13.470 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 37 | 2024 | 196 | 8.550 |
Why?
|
| Pulmonary Fibrosis | 16 | 2024 | 137 | 5.920 |
Why?
|
| Alveolitis, Extrinsic Allergic | 11 | 2024 | 42 | 2.830 |
Why?
|
| Mucin-5B | 5 | 2024 | 12 | 2.510 |
Why?
|
| Lung Transplantation | 6 | 2024 | 292 | 2.000 |
Why?
|
| Lung | 20 | 2024 | 1263 | 1.970 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2024 | 2661 | 1.940 |
Why?
|
| Connective Tissue Diseases | 10 | 2024 | 70 | 1.490 |
Why?
|
| Telomere | 8 | 2024 | 114 | 1.430 |
Why?
|
| Humans | 92 | 2024 | 89356 | 1.230 |
Why?
|
| Pyridones | 2 | 2020 | 56 | 1.220 |
Why?
|
| Registries | 7 | 2024 | 784 | 1.120 |
Why?
|
| Indoles | 2 | 2020 | 314 | 1.100 |
Why?
|
| Hospitalization | 5 | 2024 | 877 | 1.080 |
Why?
|
| Aged | 41 | 2024 | 19165 | 1.080 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2022 | 28 | 1.070 |
Why?
|
| Disease Progression | 12 | 2023 | 1489 | 1.020 |
Why?
|
| Cohort Studies | 17 | 2024 | 2872 | 1.000 |
Why?
|
| Machine Learning | 2 | 2024 | 258 | 0.980 |
Why?
|
| Fibrosis | 6 | 2023 | 234 | 0.900 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1723 | 0.880 |
Why?
|
| Male | 48 | 2024 | 42411 | 0.870 |
Why?
|
| Emphysema | 1 | 2023 | 23 | 0.870 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 36 | 0.860 |
Why?
|
| Nitric Oxide | 2 | 2022 | 279 | 0.840 |
Why?
|
| Immunosuppressive Agents | 7 | 2024 | 975 | 0.830 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 32 | 0.820 |
Why?
|
| Mediastinum | 2 | 2019 | 47 | 0.810 |
Why?
|
| Autoimmunity | 4 | 2018 | 168 | 0.800 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 25 | 0.800 |
Why?
|
| Retrospective Studies | 25 | 2024 | 9057 | 0.790 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 117 | 0.790 |
Why?
|
| Prognosis | 12 | 2024 | 3783 | 0.790 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 22 | 0.790 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.780 |
Why?
|
| Middle Aged | 36 | 2024 | 25974 | 0.780 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 32 | 0.770 |
Why?
|
| Female | 45 | 2024 | 46202 | 0.760 |
Why?
|
| Friends | 1 | 2021 | 20 | 0.750 |
Why?
|
| Genomics | 2 | 2024 | 762 | 0.750 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 322 | 0.720 |
Why?
|
| Biomarkers | 7 | 2024 | 1767 | 0.710 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 170 | 0.700 |
Why?
|
| Precision Medicine | 1 | 2024 | 410 | 0.690 |
Why?
|
| Hypertension, Pulmonary | 5 | 2022 | 353 | 0.690 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 52 | 0.690 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 249 | 0.690 |
Why?
|
| Racism | 1 | 2021 | 89 | 0.680 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 216 | 0.670 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.670 |
Why?
|
| Vital Capacity | 6 | 2024 | 68 | 0.640 |
Why?
|
| Patient Compliance | 1 | 2020 | 231 | 0.640 |
Why?
|
| Lymph Nodes | 2 | 2019 | 548 | 0.620 |
Why?
|
| Respiratory Function Tests | 6 | 2024 | 139 | 0.610 |
Why?
|
| Pandemics | 2 | 2021 | 773 | 0.600 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.580 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 286 | 0.570 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 34 | 0.570 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.560 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 851 | 0.540 |
Why?
|
| United States | 12 | 2024 | 6989 | 0.530 |
Why?
|
| Proteomics | 4 | 2024 | 230 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 2340 | 0.490 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 825 | 0.490 |
Why?
|
| Inflammation | 2 | 2024 | 972 | 0.490 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 162 | 0.480 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 242 | 0.470 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 107 | 0.460 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 136 | 0.460 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 645 | 0.440 |
Why?
|
| Leukocytes | 3 | 2023 | 204 | 0.410 |
Why?
|
| Aortic Valve Stenosis | 2 | 2011 | 143 | 0.410 |
Why?
|
| Survival Analysis | 5 | 2024 | 1534 | 0.410 |
Why?
|
| Minority Groups | 2 | 2023 | 146 | 0.400 |
Why?
|
| Risk Assessment | 6 | 2021 | 2303 | 0.390 |
Why?
|
| Prevalence | 7 | 2021 | 1243 | 0.380 |
Why?
|
| Hypoxia | 1 | 2015 | 653 | 0.340 |
Why?
|
| Referral and Consultation | 2 | 2024 | 341 | 0.330 |
Why?
|
| Survival Rate | 4 | 2020 | 1901 | 0.310 |
Why?
|
| Quality of Life | 1 | 2016 | 1668 | 0.300 |
Why?
|
| Prospective Studies | 7 | 2024 | 4289 | 0.300 |
Why?
|
| Cause of Death | 2 | 2019 | 269 | 0.290 |
Why?
|
| Echocardiography | 2 | 2022 | 938 | 0.290 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1671 | 0.270 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2284 | 0.270 |
Why?
|
| Biology | 2 | 2023 | 52 | 0.260 |
Why?
|
| Heart Failure | 1 | 2015 | 1185 | 0.260 |
Why?
|
| Adult | 11 | 2024 | 26607 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 956 | 0.260 |
Why?
|
| Eligibility Determination | 1 | 2024 | 36 | 0.240 |
Why?
|
| Phenotype | 3 | 2020 | 2440 | 0.230 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 53 | 0.220 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1597 | 0.220 |
Why?
|
| Telomerase | 2 | 2020 | 62 | 0.220 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 29 | 0.220 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 51 | 0.220 |
Why?
|
| Reference Values | 1 | 2024 | 661 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 99 | 0.220 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 148 | 0.210 |
Why?
|
| Biopsy | 4 | 2021 | 1184 | 0.210 |
Why?
|
| Age Factors | 3 | 2020 | 1870 | 0.210 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1840 | 0.210 |
Why?
|
| Shock, Septic | 1 | 2023 | 105 | 0.210 |
Why?
|
| Risk Factors | 3 | 2021 | 5499 | 0.190 |
Why?
|
| Survivors | 1 | 2023 | 234 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1072 | 0.190 |
Why?
|
| Azathioprine | 2 | 2023 | 124 | 0.190 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2021 | 100 | 0.190 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 31 | 0.190 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 88 | 0.190 |
Why?
|
| Health Services | 1 | 2021 | 57 | 0.180 |
Why?
|
| Occupational Health | 1 | 2021 | 36 | 0.180 |
Why?
|
| Hematology | 1 | 2020 | 30 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 684 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 387 | 0.180 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2021 | 87 | 0.170 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 275 | 0.170 |
Why?
|
| Aging | 1 | 2024 | 718 | 0.170 |
Why?
|
| Peroxidase | 1 | 2019 | 51 | 0.170 |
Why?
|
| Mutation | 3 | 2020 | 4143 | 0.170 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 266 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 352 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 988 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 114 | 0.160 |
Why?
|
| Genotype | 2 | 2022 | 1849 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 337 | 0.150 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 59 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2021 | 427 | 0.150 |
Why?
|
| Time Factors | 3 | 2021 | 5338 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 428 | 0.150 |
Why?
|
| Bronchiectasis | 1 | 2017 | 14 | 0.150 |
Why?
|
| Propensity Score | 1 | 2018 | 147 | 0.150 |
Why?
|
| Acetylcysteine | 1 | 2018 | 70 | 0.150 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2017 | 950 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1066 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3666 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1525 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 371 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 64 | 0.140 |
Why?
|
| Disease Management | 2 | 2016 | 329 | 0.140 |
Why?
|
| Transcriptome | 1 | 2021 | 630 | 0.140 |
Why?
|
| Cytokines | 2 | 2023 | 803 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 71 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2401 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6811 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 601 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1047 | 0.130 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 14 | 0.130 |
Why?
|
| Hypoventilation | 1 | 2015 | 6 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 28 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 91 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2018 | 681 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 105 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 471 | 0.120 |
Why?
|
| Antigens | 1 | 2016 | 229 | 0.120 |
Why?
|
| Comorbidity | 2 | 2017 | 949 | 0.120 |
Why?
|
| Logistic Models | 1 | 2018 | 1213 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 160 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 416 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 117 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 343 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 324 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2016 | 322 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 269 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1862 | 0.110 |
Why?
|
| Canada | 2 | 2023 | 208 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 458 | 0.100 |
Why?
|
| Child | 1 | 2023 | 7174 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2015 | 0.090 |
Why?
|
| Autopsy | 2 | 2021 | 122 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2019 | 8241 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2020 | 3384 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 971 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 83 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 401 | 0.070 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 516 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2362 | 0.060 |
Why?
|
| Mexico | 1 | 2024 | 70 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2024 | 126 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 146 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 19 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 207 | 0.060 |
Why?
|
| Rituximab | 1 | 2024 | 119 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 26 | 0.060 |
Why?
|
| Monocytes | 1 | 2024 | 218 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2023 | 93 | 0.050 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 48 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 302 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 20 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 146 | 0.050 |
Why?
|
| North America | 1 | 2023 | 184 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 321 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 281 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 92 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2758 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 313 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 575 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 15 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 237 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 354 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 84 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 27369 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 387 | 0.040 |
Why?
|
| Oxygen | 1 | 2024 | 743 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 187 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 320 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 479 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 788 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 352 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 102 | 0.040 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 24 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1799 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 106 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 84 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 147 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1877 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 389 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1310 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 580 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 610 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 319 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 726 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 463 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 433 | 0.030 |
Why?
|
| Chicago | 1 | 2017 | 1427 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2001 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1374 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2884 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3218 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2366 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1976 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6312 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 11761 | 0.010 |
Why?
|